6533b7dbfe1ef96bd12709a8
RESEARCH PRODUCT
Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus Gemcitabine.
Antonio FebbraroAngelica PetrilloFortunato CiardielloFernando De VitaJole VentrigliaGiuseppe TirinoValentina GambardellaA. DianaMaria Maddalena LaterzaAndrés CervantesMichele OrdituraMarisol Huerta AlvaroB. Savastanosubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseGemcitabineOncologyPancreatic cancerInternal medicineImmunologymedicineOverall survivalNeutrophil to lymphocyte ratiobusinesshuman activitieshealth care economics and organizationsNab-paclitaxelmedicine.drugdescription
e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...
year | journal | country | edition | language |
---|---|---|---|---|
2016-05-20 | Journal of Clinical Oncology |